



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/166000/>

Version: Accepted Version

Article:

Colton, H., Ankcorn, M., Yavuz, M. et al. (2021) Improved sensitivity using a dual target, E and RdRp assay for the diagnosis of SARS-CoV-2 infection : experience at a large NHS Foundation Trust in the UK. *Journal of Infection*, 82 (1). pp. 159-198. ISSN: 0163-4453

<https://doi.org/10.1016/j.jinf.2020.05.061>

Article available under the terms of the CC-BY-NC-ND licence
(<https://creativecommons.org/licenses/by-nc-nd/4.0/>).

Reuse

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) licence. This licence only allows you to download this work and share it with others as long as you credit the authors, but you can't change the article in any way or use it commercially. More information and the full terms of the licence here: <https://creativecommons.org/licenses/>

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.



Journal of Infection

Improved sensitivity using a dual target, E and RdRp assay for the diagnosis of SARS-CoV-2 infection: Experience at a large NHS Foundation Trust in the UK --Manuscript Draft--

Manuscript Number:	YJINF-D-20-02411
Article Type:	Letter to the Editor
Section/Category:	Rest of the World Submissions
Corresponding Author:	Michael Ankcorn, BSC (Hons), MBBS (Hons) Sheffield Teaching Hospitals NHS Foundation Trust London, UNITED KINGDOM
First Author:	Michael Ankcorn, BSC (Hons), MBBS (Hons)
Order of Authors:	Michael Ankcorn, BSC (Hons), MBBS (Hons) Hayley Colton Mehmet Yavuz Leeanne Tovey Alison Cope Mohammad Raza Alexander J Keeley Amy State Bozena Poller Matthew Parker Thushan I de Silva Cariad Evans
Manuscript Region of Origin:	UNITED KINGDOM

To The Editor,

We have prepared a letter for the *Journal of Infection* which we feel is of interest to many of your readers and is particularly timely.

It details our early experience of using a dual target (RdRp and E gene) real time PCR assay. As initial diagnostic algorithms for SARS-CoV-2 raised concerns of the specificity of E gene amplification in isolation due to batch contamination of reagents, we were interested in particular in analysing the samples where E gene amplified in the absence of RdRp amplification.

The principle findings are that E gene detection in the absence of RdRp detection was common (12.3%) amongst positive samples, the majority (96.9%) of which were considered true positives following further assessment. In addition, in a subset of samples where symptom onset was available (145 samples from 128 patients), it was clear that the cycle threshold values for both RdRp and E gene were lowest around 48 – 72 hours following symptom onset (Figure 2), and at each stage of infection the median CT values for RdRp were higher than those for the E gene.

We believe dual target testing, using the E gene as a second target, will help improve both laboratory diagnostic pick up and our clinical response to this pandemic. This may be particularly relevant due to the current difficulty in sourcing nucleic acid extraction kits globally, as alternative options such as PCR without a nucleic acid extraction step are being explored, which inherently reduces the sensitivity of RNA detection from clinical samples

Many thanks for your consideration.

Dr Hayley Colton & Dr Michael Ankcorn

Corresponding Author:

Dr Michael Ankcorn

michaelankcorn@nhs.net

Department of Virology, Northern General Hospital, Sheffield , UK.

Alternative corresponding author:

Dr Hayley Colton

hayley.colton@nhs.net

Department of Virology, Northern General Hospital, Sheffield , UK.

**Improved sensitivity using a dual target, E and RdRp assay for the diagnosis of SARS-CoV-2
infection: Experience at a large NHS Foundation Trust in the UK**

Hayley Colton^{*,1}, Michael Ankcorn^{*,1}, Mehmet Yavuz¹, Leeanne Tovey¹, Alison Cope¹, Mohammad Raza¹, Alexander J Keeley¹, Amy State¹, Bozena Poller¹, Matthew Parker³, Thushan I de Silva^{1,2} & Cariad Evans¹

1. Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom
2. The Department of Infection, Immunity and Cardiovascular Disease, The Medical School, The University of Sheffield, United Kingdom
3. Sheffield Biomedical Research Centre, Sheffield Bioinformatics Core, The Medical School, The University of Sheffield, United Kingdom

*= Contributed equally

Corresponding author

Dr Michael Ankcorn

michaelankcorn@nhs.net

Keywords: SARS-CoV-2; PCR; diagnosis; COVID19; RdRp gene; E gene.

Author Contributions

Hayley Colton & Michael Ankcorn – collated and analysed clinical and PCR data, prepared manuscript.

Mehmet Yavuz & Leeanne Tovey – collected data and validated E-RdRp assay.

Alison Cope – edited manuscript.

Mohammad Raza – edited manuscript.

Alexander J Keeley – collected data, edited manuscript.

Amy State – collected data, edited manuscript.

Bozena Poller – collected data, edited manuscript.

Matthew Parker – collated sequencing data, edited manuscript.

Thushan I de Silva & Cariad Evans – oversaw project, analysed data and edited manuscript.

Conflict of interest

The authors declare no conflicts of interest.

Ethics

The project was undertaken by Laboratory Medicine as part of the evaluation, validation and verification of the diagnostic test as per the Quality Assurance requirements of the relevant ISO, BSI and UKAS accreditation system. The primary aim of this work is therefore not classed as research, therefore Research Ethics Committee opinion was not required.

1 **Improved sensitivity using a dual target, E and RdRp assay for the diagnosis of SARS-CoV-2**
2 **infection: Experience at a large NHS Foundation Trust in the UK**

3 **Dear Editor,**

4 We read with interest the letter from Hao *et al* highlighting the issues regarding the
5 sensitivity of real time reverse-transcriptase polymerase chain reaction (RT-PCR) testing of upper
6 respiratory tract samples for COVID19 disease [1]. Extensive RT-PCR testing by has been key to
7 clinical decision-making, epidemiological analysis and policy development during the current severe
8 acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. The majority of RT-PCR assays
9 target the RNA-dependent RNA polymerase (RdRp), envelope protein (E) or nucleocapsid protein (N)
10 genes [2]. However, initial testing algorithms and expert opinion from the European Centre for
11 Disease Prevention and Control (ECDC) advised that E gene amplification in isolation should be
12 treated cautiously, due to concerns of non-specificity and issues related to contamination of
13 reagents [3]. Early experience at Sheffield Teaching Hospitals NHS Foundation Trust (UK) on serially
14 sampled patients with confirmed SARS-CoV-2 infection suggested that E gene detection persists
15 beyond RdRp detection, and may offer enhanced diagnostic sensitivity. Therefore we explored the
16 significance of E gene detection in relation to RdRp, and in the absence of RdRp detection in a
17 retrospective evaluation of SARS-CoV-2 RT-PCR testing.

18 A total of 12,015 clinical samples (combined nose/throat swabs or lower respiratory tract samples)
19 were tested for SARS-CoV-2 as part of routine clinical diagnostics between 2nd March 2020 and 5th
20 April 2020 at Sheffield Teaching Hospitals NHS Foundation Trust. Samples were extracted on the
21 MagnaPure96 platform (Roche Diagnostics Ltd, Burgess Hill, UK). SARS-CoV-2 RNA was detected on
22 6µl of extract using a dual target (E gene and the RdRp gene) in-house PCR on ABI Thermal Cycler
23 (Applied Biosystems, Foster City, United States) (supplementary material) [4]. The assay was
24 modified to a multiplex single-well assay with the addition of PCR primers to detect a housekeeping
25 gene, Ribonuclease P (RNase P), which acts as an internal control and to assess sample quality.

26 Of the samples tested, 2,593 samples (21.6%) were positive with amplification curves for one or
27 both target genes. Amongst positive results, we found E gene amplification alone to be common (n=
28 319, 12.3%), although the majority were positive for both RdRp and E gene targets (n = 2273, 87.7 %)
29 and only 1 sample (<0.1 %) had RdRp gene amplification alone.

30 From the E-only positive group (n=319), 69 (21.6%) samples had low level amplification in the E gene
31 (cycle threshold (CT) ≥ 35) and were investigated further. Within this subset, the majority (n=59,
32 85.5%) were considered to be true positives because they were either a) confirmed by an alternative
33 assay (n=48) or b) a preceding or subsequent sample was positive for both E and RdRp (n=11) (Table
34 1). The alternative assay employed was a modified version of the Centers for Disease Control and
35 Prevention (CDC) assay targeting the N gene (Micropathology Ltd, Coventry, UK) in most cases
36 (n=47) or an alternative RdRp assay (n=1) [7]. Six samples (8.7 %) could not be confirmed in an
37 alternative assay which had either high CT values for the E gene (n=4, CT values ≥ 39.0) or had good
38 amplification curves not reaching the threshold (n=2). To further confirm the presence of SARS-CoV-
39 2 RNA in samples with E gene only amplification, 11 samples were selected and successfully
40 underwent whole genome sequencing (supplementary material). Analysis of the RdRp primer or
41 probe binding sites in these samples did not reveal any mismatches to explain the lack of RdRp RT-
42 PCR positivity (supplementary material).

43 We further explored the relationship between E gene detection and RdRp gene detection. Amongst
44 samples with both RdRp gene and E gene amplification (n= 2273) , we found that CT values for the E
45 gene target were significantly lower than the CT values for RdRP, with a mean difference of 5.8
46 (Paired t test, p-value < 2.2e-16, 95% CI 5.79-5.92) (supplementary material). In a subset of samples
47 where symptom onset was available (145 samples from 128 patients), it was clear that the CT values
48 for both RdRp and E gene were lowest around 48 – 72 hours following symptom onset (Figure 1). At
49 each stage of infection, the median CT values for RdRp were higher than those for the E gene.

50 By using the E gene target in addition to the RdRp gene target we observed a significantly increased
51 diagnostic pick up (11.9%). In one patient, E gene amplification was detected for three days beyond
52 RdRp amplification, indicating a possible widening of the diagnostic window. Our findings confirm
53 that clinical samples with E only amplification should not be dismissed as non-specific results. Not
54 only were we able to obtain whole genome sequences for SARS-CoV-2 from a subset of this group,
55 we also found that 85% of E only samples with high CT values were confirmed by a second assay
56 targeting the N gene or an alternative RdRp only assay.

57 The enhanced sensitivity seen for the E gene in our dual target E-RdRP assay is yet to be explained.
58 We observed a mean difference of over five CT values when comparing E gene to RdRp values, which
59 may suggest the possibility of higher copy numbers of E gene being present in the primary or
60 extracted sample. Due to the unique transcription strategy of coronaviruses, genes towards the 3'
61 end of the genome would be present in higher copy numbers during active viral replication, which
62 could explain these findings [5]. It is also possible that PCR optimised conditions in a multiplex
63 system favours E gene amplification, however we found no significant loss of RdRp detection when
64 comparing single and multiplex systems during validation, with observed CT rises averaging 1-2
65 cycles (data not shown). In addition, we found no evidence of primer or probe mismatches in the
66 RdRp region.

67 We believe dual target testing, using the E gene as a second target, will help improve both diagnostic
68 sensitivity and the appropriate clinical response to this pandemic. We urge testing laboratories to
69 carefully consider the use of the E gene as a target in order to optimise SARS-CoV-2 diagnostics,
70 including strategies to confirm samples with E gene only amplification as we have described.

71 **Word count 996**

72 **Acknowledgements**

73 The authors would like to thank the Virology team at Sheffield Teaching Hospitals NHS Foundation
74 Trust for the long hours in the processing and testing of clinical specimens, and Professor Goura
75 Kudesia for her contribution towards assay validation work. We would also like to thank Andy Taylor
76 at Micropathology Laboratories, Coventry for sharing the N gene data. Sequencing of SARS-CoV-2
77 samples was undertaken by the Sheffield COVID-19 Genomics Group as part of the COG-UK
78 CONSORTIUM. The sequencing part of the validation was in part supported / funded by the NIHR
79 Sheffield Biomedical Research Centre (BRC). The views expressed are those of the author(s) and not
80 necessarily those of the NHS, the NIHR or the Department of Health and Social Care (DHSC).

81

82 **References**

- 83 1. Hao W, Li M. Clinical features of atypical 2019 novel coronavirus pneumonia with an initially
84 negative RT-PCR assay. *J Infect* **2020**; 80(6): 671-93.
- 85 2. Udugama B, Kadhiresan P, Kozlowski HN, et al. Diagnosing COVID-19: The Disease and Tools
86 for Detection. *ACS Nano* **2020**.
- 87 3. Questions and answers regarding laboratory topics on SARS-CoV-2. Available at:
88 [https://www.ecdc.europa.eu/en/all-topics-z/coronavirus/threats-and-outbreaks/covid-](https://www.ecdc.europa.eu/en/all-topics-z/coronavirus/threats-and-outbreaks/covid-19/laboratory-support/questions)
89 [19/laboratory-support/questions](https://www.ecdc.europa.eu/en/all-topics-z/coronavirus/threats-and-outbreaks/covid-19/laboratory-support/questions). Accessed 19th April.
- 90 4. Corman VM, Landt O, Kaiser M, et al. Detection of 2019 novel coronavirus (2019-nCoV) by
91 real-time RT-PCR. *Euro Surveill* **2020**; 25(3).
- 92 5. Sawicki SG, Sawicki DL, Siddell SG. A contemporary view of coronavirus transcription. *J Virol*
93 **2007**; 81(1): 20-9.
- 94 6. CDC. Real-time RT-PCR Primer and Probe Information. Available at:
95 <https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html>.
96 Accessed 19th April 2020.
- 97 7. [https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd)
98 [use-authorizations#covid19ivd](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations#covid19ivd). Accessed 19th April 2020.
- 99 8. Y-Z. Z. Novel 2019 coronavirus genome. Available from: [http://virological.org/t/novel-2019-](http://virological.org/t/novel-2019-coronavirus-genome/319)
100 [coronavirus-genome/319](http://virological.org/t/novel-2019-coronavirus-genome/319). Accessed 19th April.
- 101 9. Fomsgaard AS, Rosenstjerne MW. An alternative workflow for molecular detection of SARS-
102 CoV-2 - escape from the NA extraction kit-shortage, Copenhagen, Denmark, March 2020.
103 *Euro Surveill* **2020**; 25(14).

104

105

106

Tables & Figures

107

108

109

	n	%
Sent for confirmation at reference laboratory ^ϕ	54	78.26
- Confirmed by alternative assay	48	(88.89)
- Not confirmed	6	(11.11)
Repeat clinical sample positive	5	7.25
Previous clinical samples positive ^ψ	6	8.70
Resulted without further testing [‡]	4	5.80
Total	69	

110

111

112 **Table 1.** Summary of samples with low level E gene amplification alone (CT ≥ 35). CT, cycle threshold;
 113 E, envelope gene.

114

115 ^ϕ Most samples (n=53) were tested at Micropathology Ltd (Coventry) using a SARS-CoV-2 N gene
 116 assay using a modified CDC assay[6]. The other sample confirmed positive at PHE Colindale using an
 117 alternative SARS-CoV-2 RdRp assay.

118 ^ψ As part of the High Consequences Infectious Diseases network, Sheffield received some of the first
 119 positive patients in the United Kingdom, who had daily swabs taken. E gene amplification appeared
 120 to persist in this cohort after the RdRp became negative.

121 [‡] Four results were authorised without further testing due to high pre-test probability e.g.
 122 compatible symptoms with a confirmed household exposure to SARS-CoV-2.


123

124

125

126

127



128

129

130 **Figure 1. E and RdRp gene cycle threshold results in relation to symptom onset. E and RdRp**

131 amplification results plotted against days of symptom onset in 145 samples from 128 patients.

132 Lowest CT values were seen around day 3 of symptoms, with mean RdRp CT higher at a given day

133 compared to E gene CT value. The lines represent the smoothed conditional mean with 95%

134 confidence intervals in the grey bars. E, envelope gene; RdRp, RNA-dependent RNA-polymerase.

135

136

137

138

139

140

141

142

143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169

Supplementary Material

170 **Table S1.** Primer and Probe sequences used for RdRp and E gene detection.

Name	Sequence
RdRp gene F	GTG TGA RAT GGT CAT GTG TGG CGG
RdRp gene R	CAR ATG TTA AAS ACA CTA TTA GCA TA
RdRp gene P	6-FAM- CAG GTG GAA CCT CAT CAG GAG ATG C- BHQ1
E gene F	ACA GGT ACG TTA ATA GTT AAT AGC GT
E gene R	ATA TTG CAG CAG TAC GCA CAC A
E gene P	HEX-ACA CTA GCC ATC CTT ACT GCG CTT CG-BHQ1

171

172 Abbreviations: BHQ-1, black hole quencher; F, forward primer; HEX, HEX flourophore; P, probe; R,
173 reverse primer; 6-FAM, 6-Carboxyfluorescein flourophore.

174

175

176

177

178

179

180

181

182

Initial Result	N	%
Both RdRp+ and E+	2273	18.92
RdRp- and E+	319	2.66
RdRp+ and E-	1	<0.01
Invalid (negative internal control)	8	0.07
RdRp- and E-	9414	78.35
Total	12015	

183

184

185

Table S2. Summary results for all diagnostic samples tested for SARS-CoV-2. A total of 12,015

186

clinical samples (combined nose and throat swabs or lower respiratory tract specimens) were tested

187

for SARS-CoV-2 by PCR as part of routine clinical diagnosis over a period of approximately four

188

weeks. The results are summarised above. RdRp, RNA-dependent RNA-polymerase gene; E,

189

envelope gene.

190

191

192

Table S3. Whole Genome Sequencing of Samples with Unamplified RdRp

193

GISAID Identifier	E gene CT	RdRp gene CT	Coverage across genome	ARTIC Primer set
hCoV-19/England/SHEF-C0488/2020	31.2	NA	0.988	V3
hCoV-19/England/SHEF-BFD09/2020	32.2	NA	0.965	V2
hCoV-19/England/SHEF-BFF30/2020	32.3	NA	0.959	V1
Not Submitted Due To Low Coverage	34.7	NA	0.791	V3
hCoV-19/England/SHEF-C0567/2020	34	NA	0.946	V3
hCoV-19/England/SHEF-C05D0/2020	33.9	NA	0.995	V3
hCoV-19/England/SHEF-BFECA/2020	33.5	NA	0.885	V1
hCoV-19/England/SHEF-BFF5E/2020	31.7	NA	0.962	V1
hCoV-19/England/SHEF-C01DC/2020	34.6	NA	0.944	V1
hCoV-19/England/SHEF-BFE51/2020	32.4	NA	0.988	V1
hCoV-19/England/SHEF-BFCA2/2020	32.9	NA	0.988	V1

194

195

196

197

198

199

200

201

202


203

204

205

206

207



208

209

210

211 **Figure S1. Boxplot of E gene CT values and RdRp CT values in samples with PCR amplification**

212 **curves for both targets.** The box is defined by the interquartile range and the median value is


213 represented by the central horizontal line. CT values for the E gene target were significantly lower

214 than the CT values for RdRP, with a mean difference of 5.8 (Paired t test, p-value $< 2.2e-16$, 95% CI

215 5.79-5.92). CT, cycle threshold; RdRp, RNA-dependent RNA-polymerase gene; E, envelope gene.

216

217



219


220

221 **Figure S2. Correlation of E and N gene cycle thresholds.** A total of 53 extracts were sent to another laboratory
 222 (Micropathology Ltd, Coventry) for confirmatory testing in an N gene assay. Forty seven samples were
 223 confirmed as harbouring SARS-CoV-2 RNA with N gene amplification, 46 of which are plotted above. No
 224 significant correlation was seen between the CT values for the E gene and the confirmatory N gene assay
 225 (Pearson correlation 0.15, $p = 0.3$).

226 Abbreviations: CT, cycle threshold; RdRp, RNA-dependent RNA-polymerase gene; E, envelope gene.

227

228



229

230

231 **Figure S3. Multiple Sequence Alignment of SARS-CoV-2 Consensus Sequences.** 11 samples reactive

232 for E and not the RdRp gene were subjected to Oxford Nanopore sequencing using the artic network

233 protocol¹ to determine variation that may be present in the RdRp primer or probe sites that could

234 lead to a failure of the assay. A multiple sequence alignment was carried out for the resulting

235 consensus sequence for these samples using MAFFT (v7.450) (1) including the Wuhan-Hu-1

236 (MN908947.3) reference sequence. Numbers represent position in genome. There was no sequence

237 variation present in either primer site or the probe. Figure was produced using Jalview (2).

238

239 **References for supplementary material:**

240 1. Katoh, K. & Standley, D. M. MAFFT multiple sequence alignment software version 7:
241 improvements in performance and usability. *Mol. Biol. Evol.* **30**, 772–780 (2013).

242 2. Clamp, M., Cuff, J., Searle, S. M. & Barton, G. J. The Jalview Java alignment editor.
243 *Bioinformatics* **20**, 426–427 (2004).

244

245

246